ENX-102 dose and safety study for generalized anxiety
About this title
Read the official source — NCT06653296Researchers compared ENX-102 and placebo, tracking side effects to assess safety and tolerability in people with an anxiety condition.
Understand this study
What did researchers investigate?
Researchers compared ENX-102 and placebo, tracking side effects to assess safety and tolerability in people with an anxiety condition.
Who was this study for?
This study was for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Liverpool and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 38
- Sponsor
- Engrail Therapeutics INC
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06653296
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of ENX-102 and Determine a Dose-response for ENX-102 in Patients With Generalized Anxiety Disorder (GAD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Liverpool · Blackpool · Manchester
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared ENX-102 and placebo, tracking side effects to assess safety and tolerability in people with an anxiety condition.
Who is behind this study?
The study sponsor is Engrail Therapeutics INC.
Did this study involve medication?
Yes. The study involved medication, including ENX-102 and Placebo.
Who was this study for?
This study was for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
